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ABSTRACT
Background. Full-thickness chest wall resection (CWR)
is the preferred treatment for breast cancer (BC) patients
with extensive isolated locoregional recurrence. It remains
a challenge to select patients that will beneﬁt most from
this treatment. The aim of this study was to deﬁne prog-
nostic factors in patients who undergo CWR with curative
intent.
Methods. BC patients who underwent a CWR with cura-
tive intent for recurrence of disease between 1986 and 2006
were included in this retrospective study. Twenty-two
factors were studied in a univariate analyses, and multi-
variate stepwise Cox regression analyses was performed.
Results. Seventy-sevenpatientswereincludedinthisstudy.
The 5-year overall survival was 25%. There was one post-
operative death. Univariate analyses showed that three
prognostic factors were signiﬁcantly correlated with OS and
disease-freesurvival:(1)intervalbetweenprimarytreatment
and CWR (P = .02 and .004, respectively), (2) chemother-
apy for recurrence (P = .05 and .05, respectively), and (3)
resectionspecimensmallerthan150 cm
2(P = .03and.009,
respectively). An interval lasting[10 years between pri-
marytreatmentandCWRremainedstatisticallysigniﬁcantly
correlated with better overall survival and disease-free sur-
vival after multivariate analyses.
Conclusions. CWR is a safe treatment in patients who
have isolated extensive BC recurrence. The best survival
outcome was seen in patients after a disease-free interval of
C10 years. Existing data show that adjuvant radiotherapy
and adjuvant hormone therapy for estrogen-positive tumors
improves overall survival. Neoadjuvant chemotherapy may
be considered in individual patients.
Locoregional recurrence (LRR) after modiﬁed radical
mastectomy (MRM) for breast cancer (BC) is a worrying
event for both doctor and patient. Despite optimal local
treatment with curative intent, 60% of the patients will
develop distant metastases, although at the time of the ﬁrst
sign of LRR, two out of three patients have no any other
signs of BC recurrence.
1,2
Recently, the results of a prospective series of 1957
patients who underwent MRM have been published after a
median follow-up of 6 years. The LRR rate was 9%, and
3% of these patients had concomitant distant metastases.
3
Early detection of LRR and small tumor size predicted
better prognosis.
4–7
Options for local treatment of LRR include wide local
excision and/or radiotherapy whether or not in combination
with hyperthermia.
8 However, for small lesions, the type of
local treatment did not affect the ﬁnal outcome.
9 Another
study on the treatment of LRR after mastectomy concluded
that surgery combined with radiotherapy was the best
treatment option, with a 5-year disease-free survival (DFS)
of 27%.
10 In patients who initially underwent breast-con-
serving therapy (BCT) for BC, radiotherapy cannot be
included in the multimodal treatment for LRR. Therefore,
salvage mastectomy has to be performed, or even more
extensive surgery when the chest wall is involved. In
patients with LRR who were initially treated with BCT or
MRM, the results are similar.
2,9 After MRM and BCT, the
5-year survival rates were 58% and 59%, with subsequent
local control rates of 61% and 63%. In this study, aggressive
multimodal therapy with curative intent is recommended.
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DOI 10.1245/s10434-009-0662-7In the literature, adequate deﬁnitions for LRR, the extent
of LRR and the type of treatment these patients received are
lacking. Often it is unclear whether patients with extensive
LRR underwent chest wall resection (CWR) or not.
As a result of the heterogeneity of LRR invading the
chest wall and the scarcity of published data, there are no
evidence-based guidelines for the best treatment results.
Radiotherapy as monotherapy for extensive LRR does
not result in complete remission. Consequently, surgery
may be the best treatment option, even if it means exten-
sive surgical resection with reconstruction of the chest
wall. CWR is expected to regain local control, improve the
prognosis, and/or achieve good palliation, in combination
with limited morbidity and mortality.
In 1907, Sauerbruch introduced an extensive thoracic
wall resection procedure for recurrent breast carcinoma.
11
Since then, several reports have been published on these
procedures. There are a few large series (approximately
15), and some of them were performed at the same insti-
tute—for example, M. D. Anderson Cancer Center in the
United States, the Instituto Nazionale in Italy, and Kinki
Hospital in Japan.
12–20
The present retrospective single-center study of CWR
for recurrent BC aims to describe the outcome of treatment
and to identify prognostic factors in patients who were
treated with curative intent.
MATERIALS AND METHODS
According to our retrospective database on CWRs for
malignant tumors or radiation ulcers on the chest wall in
the period 1986 to 2006, a total of 92 of 229 consecutive
patients had undergone CWR for recurrent BC.
CWR was deﬁned as either extended soft tissue resec-
tion with broad margins that required reconstruction of the
soft tissue component, or full-thickness CWR that included
at least one rib or part of the sternum (Fig. 1). Several types
of inlay have been used for skeletal reconstruction over the
20-year study period. In the ﬁrst few years, homologous
dura mater has been used (Lyodura, B. Braun, Melsungen,
FRG), later to be replaced by polyurethane (Neuropatch, B.
Braun, Melsungen, FRG) as an artiﬁcial inlay. In some
cases, polyglactin (Vicryl, Ethicon) was used. Patients
operated on after 2004 received a double-layer poly-
propylene-polytetraﬂuoroethylene mesh (Composix).
Standard soft tissue reconstruction was performed with
pedicled omentoplasty unless primary closure could be
achieved. Surgical aspects of the CWR technique at our
hospital have been described previously.
21
Fifteen of the 92 patients were excluded from this study
because the CWR was for palliative reasons, such as
fungating ulcers or symptomatic progression of LRR, and
the prognosis was reasonable despite the presence of dis-
tant metastases and limited life expectancy. The CWR was
considered to be potentially curative when preoperative
evaluation showed that the resection could be radical and
the patient had no evidence of distant metastases. There-
fore, at least a computed tomographic scan of the lung and
of the liver, a bone scintigraphy, and mammography were
performed. Patients who had received previous radiother-
apy and/or systemic therapy for this LRR were not
excluded from our analysis. Severe complications were
deﬁned as those that required prolonged hospitalization or
resurgery.
Two clinical end points were set: (1) overall survival
(OS) deﬁned as the time from CWR to the date of death or
the date of the last visit, whichever occurred ﬁrst; (2) DFS,
deﬁned as the time from CWR to the date of local recur-
rence, or regional recurrence, or the date of death, or the
date of the last visit, whichever occurred ﬁrst.
Detailed clinical information was obtained from the
medical records and pathology reports. Patient, tumor, and
treatment characteristics at initial presentation with BC
(Table 1) and treatment and outcome factors at the time of
CWR (Table 2) were collected.
Univariate analysis was performed by the Kaplan-Meier
method and the log rank test. Multivariate analysis was
performed to determine the independent prognostic values
of the statistically signiﬁcant univariate factors by Cox’s
proportional hazard model (stepwise backward selection).
Signiﬁcance was set at a P value of B.05. All the statistical
analyses were performed with Stata, version 9.2 (Stata-
Corp, College Station, TX).
FIG. 1 Full-thickness chest wall resection for recurrent breast
cancer, including the remaining breast and radiation ulcer with
osteoradionecrosis of the costae
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In 77 patients CWR was performed for recurrent BC that
fulﬁlled our above-described curative-intent criteria. Indi-
cations were local recurrence in the chest wall (n = 41) and
regionalrecurrenceintheaxillarylymphnodes(n = 9),orin
theinternalmammarylymphnodes(n = 27).Thelastgroup
of patients is described in detail elsewhere.
22
TABLE 1 Demographics at the time of initial treatment before chest
wall resection for recurrent breast cancer
Factor n (%)
Age (y)
\40 14 (18)
C40 63 (82)
Treatment
BCT 47 (61)
MRM 27 (35)
Radiotherapy alone 3 (4)
T status
T1 19 (25)
T2 45 (58)
T3 6 (8)
T4 6 (8)
Tx 1 (1)
N status
N0 45 (58)
N1 28 (37)
N2 3 (4)
N3 0 (0)
Nx 1 (1)
Adjuvant chemotherapy
Yes 11 (14)
No 66 (86)
Adjuvant hormone therapy
Yes 19 (25)
No 58 (75)
Adjuvant radiotherapy
Yes 44 (57)
No 33 (43)
Receptor status
a
ER positive 41 (53)
ER negative 27 (35)
ER unknown 9 (12)
PR positive 28 (36)
PR negative 33 (43)
PR unknown 16 (21)
BCT breast-conserving therapy, MRM modiﬁed radical mastectomy, ER
estrogen receptor, PR progesterone receptor
a Not tested in univariate analysis because too much data are missing
TABLE 2 Characteristics of 77 patients at the time of chest wall
resection for recurrent breast cancer
Factor n (%)
Age (y)
\60 43 (56)
C60 34 (44)
Interval since primary treatment for CWR
B10 y 49 (64)
[10 y 25 (33)
Unknown 3 (4)
Pre-CWR hyperthermia
No 67 (87)
Yes 10 (13)
Pre-CWR hormone therapy
No 62 (81)
Yes 15 (19)
Pre-CWR chemotherapy
No 66 (86)
Yes 11 (14)
Pre–thorax radiotherapy
No 63 (82)
Yes 14 (18)
Recurrence rate
First 55 (65)
Second 10 (13)
Third 8 (10)
Fourth 3 (4)
Seventh 1 (1)
Resected specimen
Skin ? soft tissue 14 (18)
Bone (with or without lung) 63 (82)
Size of resection surface
\150 cm
2 62 (81)
C150 cm
2 15 (19)
Radicality
No 28 (36)
Yes 49 (64)
Bone invasion
No 32 (42)
Yes 45 (58)
Ulceration
No 67 (87)
Yes 10 (13)
Reconstruction of bone
No 17 (22)
Yes 60 (78)
Reconstruction of skin
No 51 (66)
Yes 26 (34)
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Table 1 shows the demographic data at the time of initial
treatment for BC. Age at the time of diagnosis was 28 to 86
(median 46) years, and 18% of the patients were younger
than 40 years. MRM had been performed in 61%, BCT in
35%, and radiotherapy in combination with chemotherapy
for T4 tumors in 4%. Postoperative radiotherapy was given
in 19 of the 47 MRM patients and in 25 of the 27 BCT
patients. Initial T1–T2 tumors were present in 83% of the
patients, and axillary lymph nodes were negative in 59%.
Estrogen receptor–positive tumors were found in 53%.
Various schedules of adjuvant systemic treatment after
MRM or BCT had been applied to 19 patients (25%),
according to the guidelines at that time.
Factors at the Time of CWR
Table 2 shows the demographic data at the time of
CWR. The interval between initial treatment and CWR
ranged from 0 to 33 years, with a median of 7 years. This
interval was[10 years in 34%.
Age at the time of CWR was younger than 60 years in
56%. In 65% of the patients who underwent CWR, it was
their ﬁrst recurrence of BC. In the other 22 patients, CWR
was performed because two or more episodes of recurrence
had been treated unsuccessfully in the past with systemic
therapy and/or radiotherapy. None of the patients had
surgery of the LRR before. Full-thickness CWR with bone
resection was performed in 63 patients (82%) and bone
reconstruction in 60 patients. Primary skin closure could be
achieved in 66% of the patients, most of whom (84%)
underwent bone reconstruction. Soft tissue reconstruction
was indicated in 33%: in all but one patient, pedicled
omentoplasty and split skin grafting were performed, while
17 patients needed soft tissue reconstruction combined
with bone reconstruction.
The pathology reports described tumor-free margins (R0
resection) in 64% of the CWR specimens. Adjuvant
treatment had been applied to 58% of the patients after
intensive discussion in a multidisciplinary team (Table 3).
Of the patients with no tumor-free margins, 18% received
adjuvant systemic treatment, and 54% radiotherapy and/or
hyperthermia.
Complications
Recovery without any complications was seen in 48
(62%) of 77 patients. The remaining 29 patients (38%)
had moderate or severe complications. Complications that
could be treated conservatively occurred in 12 patients,
while 16 patients (22%) had severe complications that
required resurgery or prolonged hospitalization. One
patient died within 30 days due to respiratory failure
caused by pulmonary embolism.
OS, DFS, Local Recurrence, and Metastases
Median OS of the patients who underwent CWR for
recurrent BC with curative intent was 40 months. The 1-
year and 5-year OS rates were 94% and 25%, respectively
(Fig. 1).
The 1-year and 5-year local recurrence-free rates were
81% and 51%, respectively.
Median DFS was 14.5 months. The 1-year and 5-year
DFS rates were 56% and 12%, respectively. Median
interval until (regional and distant) metastases was
18.0 months. The 1-year and 5-year metastases-free rates
were 63% and 19%, respectively.
Univariate and Multivariate Analyses
Univariate analysis showed that three prognostic factors
were signiﬁcantly related with OS and DFS: (1) interval
between primary treatment and CWR (P = .02 and .004,
respectively), (2) chemotherapy for treatment of LRR at
any time before or after CWR (P = .05 and .05, respec-
tively) and (3) resection specimen\150 cm
2 (P = .03
and .009, respectively) (Table 4).
Stepwise Cox regression analysis was performed on
interval, chemotherapy, and size simultaneously. Only an
interval of [10 years between primary treatment and
CWR remained highly correlated with better OS and
DFS.
TABLE 3 Adjuvant treatment after chest wall resection for recurrent
breast cancer (n = 37)
Adjuvant treatment n (%)
Chemotherapy 5 (13)
Hormone treatment 8 (22)
Radiotherapy 18 (49)
Hyperthermia 3 (8)
Hormone treatment and radiotherapy 2 (5)
Radiotherapy and hyperthermia 1 (3)
TABLE 2 continued
Factor n (%)
Adjuvant treatment
No 37 (48)
Yes 40 (52)
CWR chest wall resection
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Extensive isolated BC recurrence in the chest wall is
difﬁcult to manage. It is a challenge to choose the best local
treatment. Evidence-based guidelines for multimodality
treatment are not yet available for this heterogeneous group
of BC patients. A few reports focus on radiotherapy for all
kinds of LRRs after BC and mainly in patients who
underwent some type of surgery before radiotherapy was
provided.
23 In 43% to 68% of the patients, radiotherapy can
provide local control, with a reported 5- and 10-year OS of
36% to 61% and 21% to 35%, respectively.
5,23–25 In our
opinion, these percentages are relatively high because a
large number of patients with a small scar recurrence are
included, although prognosis seems to be worse when
CWR is performed after the failure of radiotherapy for BC
TABLE 4 Univariate analyses of 77 patients with chest wall resec-
tion for recurrent breast cancer
Factor Overall survival Disease-free survival
HR 95% CI P value HR 95% CI P value
Age at initial treatment
\40 y 1 1
C40 y 1.01 0.99–1.03 .50 0.99 0.98–1.01 .50
Initial surgery
BCT 1 1
MRM 0.69 0.33–1.44 .32 0.84 0.43–1.62 .60
T status
T1 1 1
T2 1.22 0.51–2.94 .65 1.00 0.49–2.05 .99
T3–T4 1.09 0.40–2.95 .87 1.47 0.63–3.46 .37
N status
N0 1 1
N1 0.67 0.32–1.40 .29 0.79 0.43–1.46 .46
N2–N3 0.90 0.21–3.84 .88 0.64 0.15–2.69 .54
Initial adjuvant chemotherapy
No 1 1
Yes 1.65 0.58–4.72 .35 2.47 0.92–6.61 .06
Initial adjuvant hormone therapy
No 1 1
Yes 0.52 0.20–1.34 .17 0.72 0.35–1.51 .39
Initial adjuvant radiotherapy
No 1 1
Yes 1.26 0.63–2.54 .52 1.46 0.80–2.64 .21
Age at CWR
\60 y 1 1
C60 y 0.99 0.97–1.01 .18 0.99 0.97–1.00 .056
Interval prim–CWR
B10 y 1 1
[10 y 0.32 0.12–0.84 .02 0.37 0.19–0.74 .004
Pre-CWR hyperthermia
No 1 1
Yes 1.17 0.45–3.02 .75 1.31 0.58–2.94 .51
Pre-CWR hormones
No 1 1
Yes 0.72 0.33–1.60 .42 0.97 0.50–1.88 .93
Pre-CWR chemotherapy
No 1 1
Yes 2.29 0.99–5.34 .05 2.26 0.99–5.13 .05
Pre-CWR radiotherapy
No 1 1
Yes 0.68 0.30–1.56 .36 0.99 0.50–1.97 .99
Recurrence rate
First 1 1
Second or
more
0.86 0.42–1.73 .66 1.44 0.79–2.61 .23
TABLE 4 continued
Factor Overall survival Disease-free survival
HR 95% CI P value HR 95% CI P value
Resected specimen
Skin ? soft
tissue
11
Bone
(?other)
0.86 0.38–1.98 .73 0.99 0.48–2.06 .99
Size resection surface
\150 cm
2 11
C150 cm
2 2.32 1.08–4.98 .03 2.4 1.22–4.70 .009
Radicality
No 1 1
Yes 1.82 0.85–3.89 .12 0.84 0.46–1.53 .57
Bone invasion
No 1 1
Yes 1.32 0.67–2.59 .42 1.19 0.65–2.20 .57
Ulceration
No 1 1
Yes 1.67 0.64–4.37 .29 1.06 0.44–2.50 .90
Reconstruction bone
No 1 1
Yes 0.99 0.46–2.12 .97 1.1 0.57–2.15 .77
Reconstruction skin
No 1 1
Yes 1.53 0.79–2.98 .21 1.73 0.97–3.10 .06
Adjuvant treatment
No 1 1
Yes 0.59 0.28–1.22 .15 0.87 0.49–1.56 .65
HR hazard ratio, 95% CI 95% conﬁdence interval, BCT breast-con-
serving therapy, MRM modiﬁed radical mastectomy, CWR chest wall
resection
Bold indicates signiﬁcant values
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26 No differences in outcome were found
between surgery and radiotherapy for small isolated lesions
of local recurrence, but aggressive multimodality treatment
was usually advised.
9,10 According to Dutch evidence-
based guidelines, surgery is recommended in combination
with hormone treatment for estrogen receptor– or proges-
terone receptor–positive tumors, but the indication for
chemotherapy is still unclear.
27,28 Several reports showed
that CWR is a safe and justiﬁable procedure with low
mortality (0 to 4.5%) and morbidity.
12,29–31 Differences in
the type of complications recorded, together with the wide
range of scoring systems in the literature, make it difﬁcult
to compare the 38% complications found in this study—
which varied from slight wound infection that could be
treated by antibiotics, to omental necrosis and pyothorax
that required additional surgery—with other studies. Mor-
tality in this study is\1% and comparable to data reported
in the literature.
The 5-year OS in our study is 25%. Most series reported
a 5-year OS of 40% to 60%.
16,29,32–34 The DFS at 5 years is
12% and only a very few series mention their results,
varying from 26% to 67% (Table 5).
35 The reason for this
difference remains unclear, but patient selection could be
an explanation. Also, our study covers a large time period,
during which aspects of BC treatment changed.
Larger series about CWR for BC make no difference
between T4 BC invading the chest wall, local recurrence
after mastectomy, axillary lymph node recurrence, internal
mammary chain recurrence, or solitary sternal metasta-
sis.
5,20,36,37 On the other hand, our median survival of
40 months is comparable with other data.Also in this series,
neithertheTandNstagenortypeofprimarysurgery,BCTor
MRM, were statistically signiﬁcant prognostic factors. In all
series, the survival curve is slightly declining after 5 years.
Fifty-one percent of our patients do not develop local
recurrence within 5 years; this result has been conﬁrmed in
another study (56%).
16
Few authors studied the inﬂuence of prognostic factors.
Age of \35 years, lymph node–negative status at initial
presentation, and an interval between initial treatment and
CWR of 2 years or 5 years were described as statistically
signiﬁcantly negative prognostic factors for OS and
DFS.
9,12,16,20,29,30,32,33,35,38,39 The multivariate analysis in
this study conﬁrmed prognostic signiﬁcance of interval
(alone) with the best results after 10 years.
If a radical (R0) resection can be expected, CWR should
beconsidered.Inthisstudy,thepathologicallyconﬁrmedR0
resection rate was 64%, which is comparable with another
report.
30 In the literature, correlations between R1 and R0
resection and DFS or OS never reached signiﬁcance.
25,29
Thiswasprobablytheresultofpostoperativeradiotherapyin
patients with a R1 resection. In discussions on the best local
treatment, CWR is preferable to radiotherapy as the ﬁrst
choice because unsuccessful radiotherapy proved to be an
important predictive factor for complications at the time of
CWR.
40 Also, the effect of radiotherapy is less in extended
and multifocal LRR, reﬂected in decreased survival.
41
The role of adjuvant systemic therapy after CWR
remains unclear, but it may be worth consideration. In
1992, a matched control study on all types of LRR treated
with excisional surgery and radiotherapy, whether or not
followed by chemotherapy or hormone therapy, showed
that OS and DFS were greatly prolonged by adjuvant
hormone therapy, but not by chemotherapy.
5 Because the
previously mentioned study was an older study, it can be
expected that with the availability of new drugs and more
effective chemotherapy schedules, the prognosis of patients
with CWR for LRR of BC will improve.
TABLE 5 Literature review of
overall survival after curative
chest wall resection for
locoregional breast cancer
recurrence
* Months median
a Univariate analysis
b After mastectomy only
c Multivariate interval 10 years
Study n 5-y survival
(%)
Local control
(follow-up)
Prognostic factors
a
Kluiber
42 12 27 m med*
Soysal
14 10 33
Faneyte
29 30 45 Age 35 y, interval 2 y
Toi
33 15 47 Interval 5 y
b
Ohuchi
32 16 57 Interval 5 y
b
Kolodziejski
43 13 62
Lequaglie
19 18 30
Miyauchi
16 23 48 56% (5 y)
Pfannschmidt
31 33 41 m med* 85% (3 y) Interval 2 y, no adjuvant chemotherapy
Downey
12 38 18 Initial node status
Warzelhan
34 22 58
Pameijer
30 22 71
Van Geel (this series) 77 25 82% (5 y) Interval,
c chemotherapy before CWR, size
Chest Wall Resection for Breast Cancer 3419To our knowledge, this is the largest study on prognostic
factors in CWR performed with curative intent for recurrent
BC. Our results conﬁrm that CWR is a safe surgical pro-
cedure. Surgery is indicated in patients who have isolated
BC recurrence, even when surgery means a CWR. The
longer the disease-free interval, the better the survival out-
come. Adjuvant radiotherapy, and for estrogen receptor–
positive tumors adjuvant hormone therapy, is indicated.
Neoadjuvant systemic therapy may be taken into consider-
ationonacase-by-casebasis.Withthisregimen,itshouldbe
possible to obtain local tumor control in approximately half
ofthepatientsandevencureatleast25%ofthepatientswith
an isolated extensive recurrence of BC in the chest wall.
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